2015 American Transplant Congress
Renal Tubular Dysfunction Following Donor Nephrectomy and Its Impact On Residual Kidney Function
Background: Recent publications have described an increasing incidence of end stage renal disease amongst kidney donors. This highlights the paucity of knowledge which exists in…2015 American Transplant Congress
Engagement of the Vasopressin Receptor On Hepatocytes Protects Liver from Ischemia-Reperfusion Injury Via the WNT-β-Catenin-SGK1-FOXO Pathway
The synthetic vasopressin analogue, terlipressin, has been extensively used in the management of certain complications associated with end-stage liver diseases (ESLDs), however concerns have been…2015 American Transplant Congress
Long-Term Efficacy and Safety of an EVR- Vs. an MMF-Based Regimen After Pediatric Kidney Transplantation (KTX): A Case-Control Study Within the CERTAIN Registry
Background: Only short-term trials using everolimus (EVR) in children after KTX have been published. Hereby we present 4 year data on low-dose ciclosporin A (CsA),…2015 American Transplant Congress
VLA-4 Blockade Inhibits Endogenous Memory CD8 T Cell-Mediated Rejection of Cardiac Allografts
Endogenous memory CD8 T cells infiltrate cardiac allografts within 24 hours of reperfusion and are activated to proliferate and produce IFN-γ in response to donor…2015 American Transplant Congress
Clinical Relevance of C3d-Binding Donor-Specific Antibodies in Late Kidney Allograft Failure
Background: The objective of this study was to investigate the prognostic value of C3d-binding donor-specific antibodies (DSA) in determining late kidney allograft failure.Methods: 1048 patients…2015 American Transplant Congress
Serum Proteins Are Significantly Upregulated in Patients With Clinical Antibody-Mediated Rejection
Background: Antibody-mediated rejection (ABMR) is a major pathway associated with late graft loss. Although serum de novo donor-specific HLA antibodies are frequently observed in ABMR,…2015 American Transplant Congress
Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced antibody-mediated rejection (ABMR) and rebound B-cell activity. Recently,…2015 American Transplant Congress
Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: Month 48 Follow-Up Results of the HERAKLES Trial
Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…2015 American Transplant Congress
Validation of the Model for End-Stage Liver Disease Score Criteria in Liver Transplantation for Acute Flare Up of Hepatitis B in Non-Cirrhotic Liver
Background: Decision of necessity of urgent liver transplantation for acute flare up of hepatitis B in the patients without cirrhosis is difficult. The MELD score…2015 American Transplant Congress
Rational Development of Alloantigen Specific Regulatory T Cell Therapy Requires Insight Into Longevity of Alloimmune Pathways
University of Cambridge, Cambridge, United Kingdom.
IntroductionWe have recently demonstrated that indirect-pathway responses against different alloantigens differ in their strength and longevity; specifically, that indirect responses against MHC class I alloantigen…
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 170
- Next Page »